Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2007

Open Access 01-12-2007 | Research

Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran

Authors: Sedigheh Zakeri, Mandana Afsharpad, Ahmad Raeisi, Navid Dinparast Djadid

Published in: Malaria Journal | Issue 1/2007

Login to get access

Abstract

Background

This work was carried out to assess the patterns and prevalence of resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) in Iran.

Methods

The prevalence of pfcrt K76T, pfmdr1 N86Y, pfdhfr N51I, C59R, S108N/T and I164L and codons S436F/A, A437G, K540E, A581E, and A613S/T in pfdhps genes were genotyped by PCR/RFLP methods in 206 Plasmodium falciparum isolates from Chabahar and Sarbaz districts in Sistan and Baluchistan province, Iran, during 2003–2005.

Results

All P. falciparum isolates carried the 108N, while 98.5% parasite isolates carried the 59R mutation. 98.5% of patients carried both 108N and 59R. The prevalence of pfdhps 437G mutation was 17% (Chabahar) and 33% (Sarbaz) isolates. 20.4% of samples presented the pfdhfr 108N, 59R with pfdhps 437G mutations. The frequency of allele pfcrt 76T was 98%, while 41.4% (Chabahar) and 27.7% (Sarbaz) isolates carried pfmdr1 86Y allele. Eight distinct haplotypes were identified in all 206 samples, while the most prevalent haplotype was T76/N86/N51R59N108/A437 among both study areas.

Conclusion

Finding the fixed level of CQ resistance polymorphisms (pfcrt 76T) suggests that CQ must be withdrawn from the current treatment strategy in Iran, while SP may remain the treatment of choice for uncomplicated malaria.
Appendix
Available only for authorised users
Literature
1.
Greenberg AE, Ntumbanzondo M, Ntula N, Mawa L, Howell J, Davachi F: Hospital based surveillance of malaria related paediatric morbidity and mortality in Kinshasa, Zaire. Bull World Health Organ. 1989, 67: 189-196.PubMedCentralPubMed
2.
Trape JF, Pison G, Preziosi MP, Enel C, Desgreés du Loû A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F: Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998, 321 (8): 689-697.CrossRefPubMed
3.
Chulay JD, Watkins WM, Sixsmith DG: Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodiumfalciparum in vitro. Am J Trop Med Hyg. 1984, 33: 325-330.PubMed
4.
Alecrim WD, Dourado H, Alecrim MG, Passos LF, Wanssa E, Albuquerque B: In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level in Amazons, Brazil. Rev Inst Med Trop Sao Paulo. 1982, 24: 52-53.PubMed
5.
Hurwitz ES, Johnson D, Campbell CC: Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine (Fansidar) in a refugee camp in Thailand. Lancet. 1981, 16: 1068-1070. 10.1016/S0140-6736(81)92239-X.CrossRef
6.
Kilimali VAEB, Mkfuya AR: In vivo assessment ofthe sensitivity of Plasmodium falciparum tosulphadoxine/pyrimethamine combinations (Fansidar) in six locationsin Tanzania where chloroquine-resistant P. falciparum hasbeen detected. Trans R Soc Trop Med Hyg. 1985, 79: 482-483. 10.1016/0035-9203(85)90071-9.CrossRefPubMed
7.
Edrissian GH, Shahabi S, Pishva E, Hajseyed-Javadi J, Khaleghian B, Ghorbani M, Emadi AM, Afshar A, Saghari H: Imported cases of chloroquine-resistant falciparum malaria in Iran. Bull Soc Path Exot. 1986, 79: 217-221.PubMed
8.
Raeisi A, Ringwald P, Safa O, Shahbazi A, Ranjbar M, Keshavarze H, Nateghpour M, Faraji L: Monitoring of the therapeutic efficacy of chloroquine for the treatment of uncomplicated, Plasmodium falciparum malaria in Iran. Ann Trop Med Parasitol. 2006, 100: 11-16. 10.1179/136485906X86220.CrossRefPubMed
9.
Edrissian GH, Afshar A, Sayedzadeh A, Mohsseni GH, Satvat MT: Assessment of the response in vivo and invitro of Plasmodium falciparum to sulphadoxine-pyrimethamine in the malarious areas of Iran. J Trop Med Hyg. 1993, 96: 237-240.PubMed
10.
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.PubMedCentralCrossRefPubMed
11.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV: A molecular marker for chloroquine- resistant falciparum malaria. N Engl J Med. 2001, 344: 257-263. 10.1056/NEJM200101253440403.CrossRefPubMed
12.
Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquineresistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002, 298: 210-213. 10.1126/science.1074045.PubMedCentralCrossRefPubMed
13.
Djimde A, Doumbo OK, Steketee RW, Plowe CV: Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet. 2001, 358: 890-891. 10.1016/S0140-6736(01)06040-8.CrossRefPubMed
14.
Sanchez C, Lanzer M: Changing ideas on chloroquine in Plasmodium falciparum. Curr Opin Infect Dis. 2000, 13: 653-658.CrossRefPubMed
15.
Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confersresistance to pyrimethamine in falciparum malaria. Proc Nat Acad Sci USA. 1988, 85: 9114-9118. 10.1073/pnas.85.23.9114.PubMedCentralCrossRefPubMed
16.
Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Das LD, Mshinda H, Tanner M, Watkins WM, Sims PFG, Hyde JE: Resistance to antifolate in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origin. Mol Biochem Parasitol. 1997, 89: 161-177. 10.1016/S0166-6851(97)00114-X.CrossRefPubMed
17.
Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000, 403: 906-909. 10.1038/35002615.CrossRefPubMed
18.
Peterson DS, Milhous WK, Wellems TE: Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA. 1990, 87: 3018-3022. 10.1073/pnas.87.8.3018.PubMedCentralCrossRefPubMed
19.
Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC: Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine and sulfamethoxazole. Am J Trop Med Hyg. 2003, 68: 586-589.PubMed
20.
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002, 185: 380-388. 10.1086/338566.CrossRefPubMed
21.
Triglia TJ, Menting JG, Wilson C, Cowman AF: Mutations in dihydropteroate synthetase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 1997, 94: 13944-13949. 10.1073/pnas.94.25.13944.PubMedCentralCrossRefPubMed
22.
Talisuna AO, Nalunkuma-Kazibwe A, Langi P, Mutabingwa TK, Watkins WW, Marck EV, Egwang TG, D'Alessandro U: Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol. 2004, 4: 321-327.CrossRefPubMed
23.
Talisuna AO, Langi P, Mutabingwa TK, Watkins W, Van Marck E, Egwang TG, D'Alessandro U: Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans R Soc Trop Med Hyg. 2003, 97: 338-342. 10.1016/S0035-9203(03)90163-5.CrossRefPubMed
24.
Nzila AM, Mberu EK, Sulo J: Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother. 2000, 44: 991-996. 10.1128/AAC.44.4.991-996.2000.PubMedCentralCrossRefPubMed
25.
Nzila AM, Nduati E, Mberu EK, Hopkins SC, Monks SA, Winstanley PA, Watkins WM: Molecular evidence of greater selective pressure for drug resistance exerted by the long acting antifolatepyrimethamine/sulfadoxine compared with the shorter-actingchlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis. 2000, 181: 2023-2028. 10.1086/315520.CrossRefPubMed
26.
Mutabingwa T, Nzila A, Mberu E: Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001, 358: 1218-1223. 10.1016/S0140-6736(01)06344-9.CrossRefPubMed
27.
Basco LK, Tahar R, Ringwald P: Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in Africa adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother. 1998, 42: 1811-1814.PubMedCentralPubMed
28.
Plowe CV: Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol. 2003, 206: 3745-3752. 10.1242/jeb.00658.CrossRefPubMed
29.
Djimde A, Dolo A, Ouattara A, Diakite S, Plowe CV, Doumbo OK: Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis. 2004, 190: 853-855. 10.1086/422758.CrossRefPubMed
30.
Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN: High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993, 61: 315-320. 10.1016/0166-6851(93)90077-B.CrossRefPubMed
31.
Duraisingh MT, Curtis J, Warhust DC: Plasmodium falciparum detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998, 89: 1-8. 10.1006/expr.1998.4274.CrossRefPubMed
32.
Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the antimalarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000, 108: 13-23. 10.1016/S0166-6851(00)00201-2.CrossRefPubMed
33.
Edrissian GH, Shahabi S: Preliminary study of the response of Plasmodium falciparum to chloroquine in Sistan and Baluchistan province of Iran. Trans R Soc Trop Med Hyg. 1985, 79: 563-564. 10.1016/0035-9203(85)90101-4.CrossRefPubMed
34.
Heidari A, Dittrich S, Jelink T, Kheirandish A, Banihashemi K, Keshavarz H: Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitol Res. 2007, 100: 589-592. 10.1007/s00436-006-0291-z.CrossRefPubMed
35.
Peterson DS, Di SS, Povoa M, Calvosa VS, Do RV, Wellems TE: Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg. 1991, 45: 492-497.PubMed
36.
Gasey GJ, Ginny M, Uranoli M, Mueller I, Reeder JC, Genton B, Cowman AF: Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Am J Trop Med Hyg. 2004, 70: 251-255.
37.
Zakeri S, Gil JP, Bereckzy S, Djadid ND, Bjorkman A: High prevalence of double Plasmodium falciparum dhfr mutations at codons 108 and 59 in the Sistan-Baluchistan province, Iran. J Infect Dis. 2003, 187: 1828-1829. 10.1086/375250.CrossRefPubMed
38.
Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, Kumar A, Ansari MA, Sharma YD: Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with Sulfadoxine-Pyrimethamine resistance. Antimicrob Agents Chemother. 2004, 48: 879-889. 10.1128/AAC.48.3.879-889.2004.PubMedCentralCrossRefPubMed
39.
Biswas S, Escalante A, Chaiyaroj S, Angkasekwinai P, Lal AA: Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Trop Med Int Health. 2000, 5: 737-743. 10.1046/j.1365-3156.2000.00632.x.CrossRefPubMed
40.
Hapuarachchi HC, Dayanath MYD, Bandara KBAT, Abeysundara S, Abeyewickreme W, De Silva NR, Hunt SY, Sibley CH: Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka. Am J Trop Med Hyg. 2006, 74: 198-204.PubMed
41.
Mita T, Kaneko A, Hwaihwanje I, Tsukahara T, Takahashi N, Osawa H, Tanabe K, Kobayakawa T, Bjorkman A: Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea. Infect Genet Evol. 2006, 6: 447-452. 10.1016/j.meegid.2006.02.004.CrossRefPubMed
42.
Wang P, Read M, Sims PFG, Hyde JE: Sulfadoxine resistancein the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol. 1997, 23: 979-86. 10.1046/j.1365-2958.1997.2821646.x.CrossRefPubMed
43.
Cox-Singh J, Zakaria R, Abdullah MS, Rahman HA, Nagappan S, Singh B: short report: differences in dihydrofolate reductase but not dihydropteroate synthetase alleles in Plasmodium falciparum isolates from geographically distinct areas in Malaysia. Am J Trop Med Hyg. 2001, 64: 28-31.PubMed
44.
Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Bras JL, Deloron P: DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother. 2003, 52: 43-49. 10.1093/jac/dkg294.CrossRefPubMed
45.
Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira daSilva LH, Zalis MG: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthetase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000, 95: 721-728. 10.1590/S0074-02762000000500020.CrossRefPubMed
46.
Keen J, Farcas GA, Zhong K, Yohanna S, Dunne MW, Kain KC: Real-Time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India. J Clin Microbiol. 2007, 45: 2889-2893. 10.1128/JCM.02291-06.PubMedCentralCrossRefPubMed
47.
Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, Subbarao SK, Ghosh SK, Tiwari SN, Sathyanarayan TS, Deshpande PR, Mishra GC, Ranjit MR, Dash AP, Rangarajan PN, Padmanaban G: Widespread occurrence of the Plasmodium falciparum chloroquine resistance transporter(PFCRT) gene haplotype SVMNT in P. falciparum malaria in India. Am J Trop Med Hyg. 2004, 70: 256-259.PubMed
Metadata
Title
Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran
Authors
Sedigheh Zakeri
Mandana Afsharpad
Ahmad Raeisi
Navid Dinparast Djadid
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2007
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-6-148

Other articles of this Issue 1/2007

Malaria Journal 1/2007 Go to the issue

Review

The safety of artemisinins during pregnancy: a pressing question

Research

Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study

Research

Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals

Case study

Pilot feasibility study of an emergency paediatric kit for intra-rectal quinine administration used by the personnel of community-based health care units in Senegal

Case report

Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C

Research

Germinal center architecture disturbance during Plasmodium berghei ANKA infection in CBA mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits